AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 21 min read

HC Wainwright & Co. reiterates Buy rating on Cullinan Therapeutics, $35 price target

HC Wainwright reiterated a Buy rating on Cullinan Therapeutics with a $35 price target, implying 140.9% upside from the Oct 1 close. The firm cited strong clinical data for zipalertinib, including a 65% overall response rate, and potential milestone payments of $100 million upon approval.

Original reporting
tradingview.com
Published Oct 2, 2026, 10:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 10:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright & Co. reiterates Buy rating on Cullinan Therapeutics, $35 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The analyst's target implies a 140% upside, likely prompting buying interest.

02

Market read

New clinical data and a raised price target provide a fresh catalyst for CLLN.

03

What to watch

Potential competition from other zipline inhibitors could limit market share.

Relevance 8/10Novelty 8/10Timing: today

Background

HC Wainwright analyst note reiterates a buy rating with a $35 target based on new zipalertinib data.

Market effects

Sector

Boosts sentiment for oncology biotech sector.

Regional

U.S. biotech investors may increase exposure.

Global

Limited to markets tracking biotech pipelines.

Counterpoint

What could challenge this read

Milestone payments are contingent on FDA approval, which remains uncertain.

Key entities

  • company
    Cullinan Therapeutics

    Biotech developing zipalertinib for cancer treatment.

  • research_firm
    HC Wainwright & Co.

    Equity research firm issuing the rating.

Read at source← All news

Related articles

OCT 19
$CGEMMedAI 8/10

Responses in the brain to an experimental lung cancer drug lasted a median 9.7 months.

Taiho Oncology and Cullinan Therapeutics (CGEM) reported that zipalertinib, an experimental lung cancer drug, showed clinically meaningful intracranial antitumor activity in a Phase 2b trial. Among 43 patients, it achieved a 67.4% intracranial objective response rate. The drug is being evaluated for NSCLC with EGFR mutations and active CNS metastases. Results will be presented at ESMO Congress 2026.

stocktitan.net2 min
OCT 2
MedAI 8/10

Cullinan Therapeutics starts zipalertinib NDA submission

Cullinan Therapeutics (CGEM) began submitting an NDA for zipalertinib in combination with chemotherapy for first-line lung cancer under FDA's real-time review program. The Phase 3 trial showed median progression-free survival of 14.5 months for the combination vs. 8.5 months for chemotherapy alone. Cullinan expects to complete the submission by year-end 2026. Shares closed at $14.53, down 5.34%.

mugglehead.com2 min